The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.
 
Kamran A. Ahmed
Research Funding - Bristol-Myers Squibb; Genentech/Roche
 
Youngchul Kim
No Relationships to Disclose
 
Sachin M. Apte
No Relationships to Disclose
 
Hye Sook Chon
No Relationships to Disclose
 
Jing-Yi Chern
No Relationships to Disclose
 
Jose Conejo-Garcia
No Relationships to Disclose
 
Daniel Celestino Fernandez
No Relationships to Disclose
 
Mitchel Hoffman
No Relationships to Disclose
 
Sungjune Kim
Stock and Other Ownership Interests - Neovasc, Inc.
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Provisional patent for lung adenocarcinoma biomarker to predict distant metastasis among stage I patients. (Inst)
 
Cesar Lam
No Relationships to Disclose
 
Michael E. Montejo
No Relationships to Disclose
 
Mian M. Shahzad
No Relationships to Disclose
 
Robert Michael Wenham
Stock and Other Ownership Interests - Ovation Diagnostics
Honoraria - Tesaro
Consulting or Advisory Role - Clovis Oncology; Genentech; Merck; Mersana; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro
Research Funding - Merck (Inst); Prescient Therapeutics (Inst)
Travel, Accommodations, Expenses - TapImmune Inc.